Author:
Xu Jia,Jin Xiao-li,Shen Hao,Chen Xuan-wei,Chen Jin,Huang Hui,Xu Bin,Xu Jian
Abstract
AbstractNOTCH receptor 3 (NOTCH3) is known to regulate the transcription of oncogenes or tumor suppressor genes, thereby playing a crucial role in tumor development, invasion, maintenance, and chemotherapy resistance. However, the specific mechanism of how NOTCH3 drives immune infiltration in gastrointestinal cancer remains uncertain. The expression of NOTCH3 was analyzed through Western blot, PCR, Oncomine database, and the Tumor Immune Estimation Resource (TIMER) site. Kaplan–Meier plotter, PrognoScan database, and gene expression profile interactive analysis (GEPIA) were used to assess the impact of NOTCH3 on clinical prognosis. The correlation between NOTCH3 expression and immune infiltration gene markers was investigated using TIMER and GEPIA. NOTCH3 was found to be commonly overexpressed in various types of gastrointestinal tumors and was significantly associated with poor prognosis. Furthermore, the expression level of NOTCH3 showed a significant correlation with the tumor purity of gastrointestinal tumors and the extent of immune infiltration by different immune cells. Our findings suggest that NOTCH3 may act as a crucial regulator of tumor immune cell infiltration and can serve as a valuable prognostic biomarker in gastrointestinal cancers.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. Arhin, N. D. et al. Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. Cancer Med. 10, 4269–4281 (2021).
2. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer J. Clin. 68, 394–424 (2018).
3. Xiao, J. et al. miR-639 Expression is silenced by DNMT3A-mediated hypermethylation and functions as a tumor suppressor in liver cancer cells. Mol. Ther. J. Am. Soc. Gene Ther. 28, 587–598 (2020).
4. Cheng, C. et al. Functional inhibition of lactate dehydrogenase suppresses pancreatic adenocarcinoma progression. Clin. Transl. Med. 11, e467 (2021).
5. Topalian Suzanne, L., Drake Charles, G. & Pardoll, D. M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).